BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-A1912 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-A1912\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06929624-11073@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-A1912: Phase 3 readout est. (NCT06929624)
DESCRIPTION:SHR-A1912\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx i
 n Diffuse Large B-cell Lymphoma\nEstimated primary completion: March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1912#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06929624
URL:https://assetmemo.bio/drug/shr-a1912#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
